Brief: Expres2ion Biotech Holding Reports First Immunogenicity Results From Phase I
04/09/2025 08:57
Sept 4 (Reuters) - ExpreS2ion Biotech Holding AB EXPRS2.ST: REPORTS FIRST IMMUNOGENICITY RESULTS FROM PHASE I TRIAL DATA, DERIVED FROM FIRST PATIENT ENROLLED IN TRIAL, INDICATE THAT VACCINE IS TRIGGERING SIGNIFICANT IMMUNE RESPONSE SIGNIFICANT INCREASE IN HER2 ANTIBODIES AFTER SECOND DOSE Source text: ID:nWkr1thxWH Further company coverage: EXPRS2.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on ExpreS2ion Biotech Holding AB
See all newsBrief: Expres2ion Biotech To Raise SEK 19.3 Million From Warrants And Share Issue
Brief: ExpreS2ion Reports Q2 Loss Of SEK 9.7 Million
Brief: Expres2ion Biotech Says DSMB Recommends Expanding 450 Μg Cohort
Brief: Expres2ion Biotech Holding Q1 2026 Operating Income SEK 6.87 Mln
Brief: Expres2ion Updates ES2B-C001 Phase I Programme and Reports Additional Preliminary Immunogenicity and Safety Observations